Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5852MR)

This product GTTS-WQ5852MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5852MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2669MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ4184MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ10170MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ2536MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ82MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ2507MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ8847MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ7226MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW